Tuesday, October 13, 2026

EUR/CHF Went Down By Over 1% In The Last 21 Sessions

ViaNews Editorial Team

January 5, 2024

EUR/CHF Went Down By Over 1% In The Last 21 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.69% for the last 21 sessions. At 09:06 EST on Friday, 5 January, EUR/CHF (EURCHF) is $0.93.

EUR/CHF's yearly highs and lows, it's 3.09% up from its 52-week low and 7.804% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.23%, a negative 0.11%, and a positive 0.27%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.31% (last week), 0.27% (last month), and 0.27% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy soars above the 143.00 figure on US bond yields advance. According to FXStreet on Wednesday, 3 January, "The USD/JPY daily chart depicts the pair as downward biased despite posting a leg-up of more than 140 pips, above the 143.00 figure. ", "Even though the USD/JPY is skyrocketing during Wednesday's session, upside risks remain, with additional US economic data pending to be released. "
  • Usd/jpy analysis: gains May remain cautious - 03 January 2024. According to DailyForex on Wednesday, 3 January, "As trading in 2024 began, the USD/JPY pair attempted to recover, with gains reaching the 142.41 resistance level, which is stable at the time of writing."
  • Usd/jpy hesitates just shy of 143.75. According to FXStreet on Wednesday, 3 January, "The USD/JPY drove higher on Wednesday as the US Dollar (USD), the day's single best-performing currency clambered over the Yen (JPY), the day's biggest loser. ", "The USD/JPY climbed one and a third percent bottom-to-top for the midweek market session, slipping back from just below 143.75 to wrap up Wednesday's trading just above the 143.00 handle."
  • Usd/jpy rallies on the back of strong US labor market figures. According to FXStreet on Thursday, 4 January, "In Thursday's trading session, the USD/JPY pair has seen a rally, rising to multi-week highs of 147.70with a robust 1% uptick. "
  • According to FXStreet on Wednesday, 3 January, "Another negative session for the Japanese yen saw USD/JPY climb to the 143.70 region on the back of the continuation of the upside momentum of US yields and a directionless patter in JGB 10-year yields."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com